文献速递骨质疏松与钙磷/甲状旁腺

Burosumab 在 X 连锁低磷血症儿童中长期有效性与安全性

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该开放标签、多中心、随机、剂量探索试验纳入 5–12 岁 XLH 儿童,先常规治疗洗脱 1 周,随机分 Q2W 与 Q4W 组治疗 64 周,第 66–160 周统一 Q2W。160 周时佝偻病严重度评分显著下降,血磷维持正常范围,耐受性良好。

要点

  • Burosumab 治疗 160 周可显著改善 XLH 儿童佝偻病严重度评分。
  • 空腹血磷升高在整个研究期间维持,第 160 周均值在儿童正常范围。
  • 长期安全性与此前报告一致,多数不良事件为轻至中度。

核心结论

  • XLH 儿童接受 burosumab 治疗 160 周可改善磷酸盐稳态与佝偻病,且耐受性良好。

研究设计与样本

  • 开放标签、多中心、随机、剂量探索试验,5–12 岁 XLH 儿童随机分 Q2W 与 Q4W 组治疗 64 周,第 66–160 周统一 Q2W。

主要发现

  • 41 例股骨远端与胫骨近端生长板未闭合儿童的总佝偻病严重度评分从基线至第 160 周显著下降 0.9 ± 0.1(最小二乘均值 ± SE;P < 0.0001)。
  • 空腹血磷升高在整个研究期间维持,第 160 周总体人群均值(SD)为 3.35(0.39)mg/dL,位于儿童正常范围(3.2–6.1 mg/dL),较基线变化 P < 0.0001。
  • 多数不良事件为轻至中度。

关键数值与推荐

  • 总佝偻病严重度评分较基线下降 0.9 ± 0.1(P < 0.0001)。
  • 第 160 周空腹血磷均值 3.35(0.39)mg/dL,儿童正常范围 3.2–6.1 mg/dL,较基线变化 P < 0.0001。

临床怎么用

  • 对 5–12 岁 XLH 儿童,burosumab 长期治疗可维持血磷并改善佝偻病,用药期间需监测血磷与不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In X-linked hypophosphatemia (XLH), excess fibroblast growth factor-23 causes hypophosphatemia and low calcitriol, leading to musculoskeletal disease with clinical consequences. XLH treatment options include conventional oral phosphate with active vitamin D, or monotherapy with burosumab, a monoclonal antibody approved to treat children and adults with XLH. We have previously reported outcomes up to 64 weeks, and here we report safety and efficacy follow-up results up to 160 weeks from an open-label, multicenter, randomized, dose-finding trial of burosumab for 5- to 12-year-old children with XLH. METHODS: After 1 week of conventional therapy washout, patients were randomized 1:1 to burosumab every 2 weeks (Q2W) or every 4 weeks (Q4W) for 64 weeks, with dosing titrated based on fasting serum phosphorus levels between baseline and week 16. From week 66 to week 160, all patients received Q2W burosumab. RESULTS: Twenty-six children were randomized initially into each Q2W and Q4W group and all completed treatment to week 160. In 41 children with open distal femoral and proximal tibial growth plates (from both treatment groups), total Rickets Severity Score significantly decreased by 0.9 ± 0.1 (least squares mean ± SE; P < 0.0001) from baseline to week 160. Fasting serum phosphorus increases were sustained by burosumab therapy throughout the study, with an overall population mean (SD) of 3.35 (0.39) mg/dL, within the pediatric normal range (3.2-6.1 mg/dL) at week 160 (mean change from baseline P < 0.0001). Most adverse events were mild to moderate in severity. MAIN CONCLUSIONS: In children with XLH, burosumab administration for 160 weeks improved phosphate homeostasis and rickets and was well-tolerated. Long-term safety was consistent with the reported safety profile of burosumab. CLINICALTRIALS.GOV: NCT02163577.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Linglart A, Imel EA, Whyte MP, et al. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. J Clin Endocrinol Metab. 2022. PMID: 34636899. doi:10.1210/clinem/dgab729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。